Molecular Vision 2026; 32:354-369
<http://www.molvis.org/molvis/v32/354>
Received 12 November 2025 |
Accepted 20 August 2026 |
Published 28 August 2026
Peirong Song,1 Hao Chen,1 Xinwei Wang,1,3 Kaier Zhang,1 Wenshuo Han,1 Yu Gu,1 Guohu Di,1 Dianqiang Wang,2 Minghong Zhang,2 Peng Chen1,4
The first two authors contributed equally to this work.
1School of Basic Medicine, Qingdao University, Qingdao, China; 2Aier Academy of Ophthalmology, Central South University, Changsha, China; 3Qingdao Cardiovascular Hospital, Qingdao, China; 4Institute of Stem Cell Regeneration Medicine, School of Basic Medicine, Qingdao University, Qingdao, Shandong, China
Correspondence to: Peng Chen, Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Qingdao, University, 308 Ningxia Road, Qingdao 266071, China; [email protected]
Purpose: Cataract is a common blinding eye disease caused by lens opacity. Emerging evidence suggests that aquaporin 5 (AQP5) deficiency may accelerate aging in an immortalized human lens epithelial cell line (SRA01/04). This study investigates whether AQP5 deficiency induces ferroptosis in these cells and explores how galangin (Gal) may slow the progression of lens opacity.
Methods: Using Aqp5 knockout (Aqp5−/−) mice and SRA01/04 cells, we evaluated ultrastructural changes via transmission electron microscopy. We also examined the Nrf2/SLC7A11/GPX4 pathway using western blot and immunofluorescence. To assess key molecular and cellular markers, we used fluorescent probes for lipid peroxidation (BODIPY C11), intracellular and mitochondrial Fe2+ levels (FerroOrange/Mito-FerroGreen), mitochondrial reactive oxygen species (MitoSOX), mitochondrial membrane potential (JC-1), and mitochondrial permeability transition pore (mPTP) opening (Calcein-AM). Experimental treatments included the ferroptosis inhibitor ferrostatin-1 (Fer-1), the Nrf2 activator artemisitene (AT), and Gal.
Results: Intervention in AQP5 expression, either through pharmacologic inhibition or gene downregulation, induced ferroptosis. This process involved intracellular and mitochondrial Fe2+ accumulation, increased lipid peroxidation, mitochondrial dysfunction (e.g., membrane depolarization, mPTP opening, and elevated reactive oxygen species), and suppression of the Nrf2/SLC7A11/GPX4 signaling pathway. Fer-1, AT, and Gal effectively reversed AQP5 deficiency-induced ferroptosis and restored the Nrf2/SLC7A11/GPX4 pathway. Intraperitoneal administration of Gal effectively reduced cataract formation in Aqp5-/- knockout mice. Its protective effects were mainly mediated through Nrf2 pathway activation, as shown by the loss of protection when Nrf2 was inhibited by brusatol.
Conclusions: AQP5 deficiency promoted ferroptosis by inhibiting the Nrf2/SLC7A11/GPX4 pathway, contributing to cataract formation. Gal showed therapeutic potential by activating this pathway, suggesting a promising approach for cataract prevention and treatment.
Cataracts remain a leading cause of global blindness [1,2]. A cataract is the opacification of the lens, with age-related cataracts (ARCs) being the most common type. The lens, a biconvex structure in the eye, transmits and refracts light [3]. The lens epithelial cells (LECs) maintain lens transparency and homeostasis, and they proliferate to aid in repair and regeneration after surgery or injury [4]. Oxidative stress is a key factor in lens aging and cataract formation [5]. Nuclear factor erythroid 2–related factor 2 (Nrf2) is crucial for the cellular antioxidant response by reducing lipid peroxidation and inhibiting ferroptosis [6]. In LECs treated with endoplasmic reticulum stressors, especially cataractogenic ones, Nrf2 expression is significantly reduced [7,8].
Mitochondria in most eukaryotic cells produce energy through oxidative phosphorylation and lipid oxidation [9]. They also generate reactive oxygen species (ROS) and become targets of ROS [10]. A hallmark of oxidative stress is increased ROS levels due to mitochondrial dysfunction [11]. The mitochondria-targeted peptide SS31 protects HLEB-3 cells from oxidative damage, reduces ROS, maintains mitochondrial membrane potential (MMP), and inhibits JNK and p38 pathway activation [12].
Ferroptosis is a form of programmed cell death caused by the accumulation of lipid peroxides, which depends on iron [13]. Iron, as a component of many metalloproteins, is crucial for biochemical processes such as electron transfer, oxygen transport, DNA synthesis, and repair [14]. However, excessive iron in cells disrupts redox balance and catalyzes ROS production, causing oxidative stress [14]. The activation of RSL3 decreases the inflammatory response and enhances ferroptosis resistance in microglia and macrophages via upregulating Nrf2 [15]. Glutathione peroxidase 4 (GPX4) [16,17] and solute carrier family 7 member 11 (SLC7A11) are key regulators of ferroptosis [18]. SLC7A11 and high solute carrier family 3 member 2 (SLC3A2) together form a critical cellular antioxidant system, Xc- [19,20]. Emerging evidence has demonstrated that activation of the Nrf2/SLC7A11/GPX4 signaling axis effectively suppresses ferroptosis in various disease models, including ocular disorders [21,22].
As a member of the aquaporin (AQP) family, aquaporin 5 (AQP5) plays a critical role in eye physiology and disorders [23,24]. In addition to transporting water, AQP5 can transport H2O2 as a peroxiporin [25]. AQP5 is expressed in the lens of humans [26], mice [25], and rats [27]. Changes in its distribution and structure may alter its functional roles in different lens regions [26]. Both human and mouse salivary glands affected by Sjögren’s syndrome show decreased GPX4 and AQP5 levels alongside increased interferon-γ production [28,29]. The reduced GPX4 in salivary gland epithelial cells impairs salivary secretion via the lipid ROS/pSTAT4/AQP5 pathway [30].
Galangin (Gal) is a naturally occurring flavonoid compound that is widely distributed in natural products such as Alpinia officinarum Hance, Plantago depressa Willd, and propolis [31]. This compound possesses pleiotropic biological activities, including antioxidant, anti-inflammatory, and antitumor properties, and has shown therapeutic potential in various disease models [32,33]. Recent studies have further revealed that Gal can inhibit ferroptosis by regulating iron metabolism and oxidative stress pathways [34,35]. Specifically, Gal has been shown to exert neuroprotective effects by activating the Nrf2/Keap1 pathway in cellular and animal models of Parkinson disease [36]. It is suggested that it has the characteristic of multitarget regulation of the ferroptosis pathway [37]. Although the above findings highlight the potential value of Gal as an inhibitor of ferroptosis, there is still a significant knowledge gap in its molecular mechanism in lens diseases.
Our prior study demonstrated that mouse primary LECs from Aqp5 knockout (Aqp5−/−) mice exhibit mitochondrial dysfunction compared with wild-type (Aqp5+/+) controls [38]. Building on this foundation, we now report an increase in lipid peroxidation and Fe2+ accumulation in LECs–hallmarks of ferroptosis. Critically, we identified suppression of the Nrf2/SLC7A11/GPX4 pathway as the mechanistic link between AQP5 deficiency and ferroptosis-driven lens epithelial damage. Furthermore, Gal counteracted this process by activating the Nrf2/SLC7A11/GPX4 axis, thereby inhibiting ferroptosis in an immortalized human lens epithelial cell line (SRA01/04). These findings elucidated a previously unrecognized pathogenic cascade in cataractogenesis and provided experimental evidence for targeting ferroptosis via Nrf2 activation as a novel therapeutic strategy.
Aqp5−/− mice were generated using CRISPR/Cas9 technology provided by Cyagen Biosciences (Guangzhou, China). All procedures were conducted according to the Institutional Animal Care and Use Committee guidelines and were approved by the Laboratory Animal Ethics Committee of Qingdao University (Approval No. QDU-AEC-2025091).
In vivo treatments were conducted on 6-month-old male Aqp5−/− mice. The animals were randomly divided into five experimental groups (n = 6 per group): the Aqp5−/− + phosphate-buffered saline (PBS) group received daily intraperitoneal injections of PBS for 4 weeks. The Aqp5−/− + ferrostatin-1 (Fer-1) group was administered Fer-1 (MCE #HY-100579; 2 mg/kg) via intraperitoneal injection every 48 h over the same period. The Aqp5−/− + Gal group received daily intraperitoneal injections of Gal (Gal, MCE #HY-N0382; 30 mg/kg) for 4 weeks. The Aqp5−/− + Gal + brusatol (Bru) group was treated daily with a combination of Gal (30 mg/kg) and Bru (MCE #HY-19543; 1 mg/kg in PBS) via intraperitoneal injection. All treatments commenced at 6 months of age. For slit-lamp examination, images were coded and evaluated by two independent observers blinded to group assignments, and lens opacity was scored using the LOCS II system. Twenty-four hours after the final injection, the mice were euthanized, and their lenses were harvested for slit-lamp examination and western blot analysis.
Primary LECs were isolated from mouse lenses following established enzymatic digestion protocols [39]. SRA01/04 were obtained from Guangzhou Cellcook Biotechnology Co., Ltd. (Guangzhou, China) and cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM; HyClone, Wilmington, DE), supplemented with 10% fetal bovine serum (Excell Bio, Shanghai, China) at 37 °C under a 5% CO2 atmosphere. For pharmacologic intervention, confluent cells were pretreated for 24 h with the following agents: 500 μM aquaporin inhibitor acetazolamide (AZ; MCE #HY-B0782), 2 μM Fer-1 (MCE), 2 μM Nrf2 activator artemisitene (AT; MCE #HY-122550), and 20 μM Gal (MCE).
Short hairpin RNAs (shRNAs) targeting human AQP5 were cloned into the pLenti–U6–shRNA–CMV–Puro lentiviral vector (abm). The sequences used were as follows: shAQP5, 5′-GAG TGA GCG TGT GGC CAT CAT CTT CAA GAG AGA TGA TGG CCA CAC GCT CAC TC-3′, and nontargeting control (shNC), 5′-GGG TGA ACT CAC GTC AGA ATT CAA GAG ATT CTG ACG TGA GTT CAC CC-3′. At 48 h posttransfection, the viral supernatant was harvested, filtered, and used to infect SRA01/04 cells at a multiplicity of infection of 20. Twelve hours after infection, the viral medium was replaced with fresh growth medium. The cells were cultured for an additional 48 h and then transferred to medium supplemented with 2.5 μg/ml puromycin (Beyotime #ST551) for 7 days. Stably transfected cell lines were selected and validated by western blot to confirm efficient AQP5 knockdown.
The cells were fixed with 4% paraformaldehyde for 20 min and subsequently blocked with 5% bovine serum albumin for 1 h at room temperature. Following this, the cells were incubated overnight at 4 °C with primary antibodies targeting AQP5 (ABclonal #A9927, Woburn, MA), Nrf2 (CST #12721), SLC7A11 (Huabio #HA600098, Hangzhou, China), and GPX4 (Huabio #ET1706–45). The next day, the cells were exposed to a fluorescein-conjugated secondary antibody (Life Technologies, Invitrogen) for 1 h at room temperature. Nuclei were then stained with DAPI for 5 min, and fluorescent images were acquired using an Olympus fluorescence microscope. Fluorescence images were analyzed using ImageJ software. For each independent biologic replicate, at least six random fields of view were captured, and the fluorescence intensity was quantified. The average intensity per field was used for statistical analysis.
Mitochondrial ROS (mtROS) were assessed using MitoSOX Red (Yeasen #1003197–00–9, Gaithersburg, MD), a fluorescent probe specifically designed for detecting superoxide in live cells. Following a 20-min incubation with MitoSOX Red in Hanks’s balanced salt solution at 37 °C in the dark, cells were washed three times with prewarmed PBS. Fluorescence images were then acquired using an Olympus fluorescence microscope (Tokyo, Japan).
Mitochondrial membrane potential (MMP) was evaluated using the JC-1 Assay Kit (Beyotime #C2003S, Shanghai, China). Following incubation with the JC-1 working solution for 20 min at 37 °C in the dark, cells were washed twice with prewarmed assay buffer (37 °C) and subsequently analyzed using an Olympus fluorescence microscope. JC-1 exhibits a membrane potential–dependent accumulation pattern in mitochondria: a high ΔΨm promotes the formation of red fluorescent J-aggregates, while a low ΔΨm leads to the accumulation of green fluorescent J-monomers.
The mitochondrial permeability transition pore (mPTP) assay kit (Beyotime #C2009S) was employed to assess mitochondrial permeability transition pore (mPTP) opening. Cells were first washed twice with PBS and subsequently incubated with the working solution at 37 °C for 30 min in the dark. Following this, the cells were transferred to high-glucose DMEM and incubated for an additional 30 min under the same conditions. Finally, the cells were washed three times and analyzed using an Olympus fluorescence microscope. A decrease in mitochondrial green fluorescence corresponded to increased mPTP opening, whereas stronger fluorescence indicated reduced mPTP opening.
Whole-cell lipid peroxidation was assessed using BODIPY 581/591 C11 (Invitrogen #D3861). Briefly, cells were incubated with 2 μM of the probe in serum-free DMEM at 37 °C in the dark for 30 min, washed twice with PBS, and visualized using an Olympus microscope. The fluorescence of the probe shifts from red (unoxidized form) to green (oxidized form). Mitochondrial lipid peroxidation was evaluated using Mito-PeDPP (Dojindo #M466, Kumamoto, Japan), a mitochondria-targeted fluorescent probe that specifically binds to oxidized lipids (excitation/emission: 540/590 nm). Cells were treated with 0.5 μM Mito-PeDPP in Hanks’s balanced salt solution at 37 °C in the dark for 15 min, washed twice with PBS, and analyzed using an Olympus fluorescence microscope.
Cytosolic and mitochondrial Fe2+ levels were measured using FerroOrange (Maokong #MX4559, Taipei, Taiwan) and Mito-FerroGreen (Dojindo #M489), respectively. For cytosolic Fe2+ detection, cells were washed twice with PBS and subsequently incubated with 1 μM FerroOrange at 37 °C for 30 min in the dark. For the quantification of mitochondrial Fe2+, cells were incubated in the dark at 37 °C for 30 min with a staining solution containing 5 μM Mito-FerroGreen and 200 nM Mito-Tracker Red CMXRos. After two additional washes, the cells were analyzed using the same fluorescence microscope (Olympus).
The cells or tissues were lysed using RIPA buffer (Beyotime). The lysates were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (EPizyme, Cambridge, MA) and then transferred onto PVDF membranes (Millipore, Darmstad, Germany). The membranes were incubated with primary antibodies against Nrf2 (Zenbio #R380773, Durham, NC), SLC7A11 (Zenbio #R382036), SLC3A2 (Upin Bio #YP-Ab-14062), GPX4 (Huabio #ET1706–45), and β-actin (Huabio #R1207–1). Following this, the membranes were treated with horseradish peroxidase–conjugated secondary antibodies (Affinity Biotechnology, Cincinnati, OH). Protein bands were detected using a Tanon imaging system (Tanon, Shanghai, China), and protein expression levels were normalized to β-actin using ImageJ densitometry.
The lens capsule was carefully dissected and fixed in a stationary solution for electron microscopy. It was subsequently postfixed with 1% osmium tetroxide. After dehydration and embedding, ultrathin sections (60–80 nm) were cut and stained with 2% uranyl acetate, followed by lead citrate. The sections were then examined using a transmission electron microscope, and the resulting images were captured and analyzed.
Data analysis was performed using GraphPad Prism 9. The Student t test was used for comparisons between two groups, whereas one-way ANOVA was applied for comparisons across multiple groups. Statistical significance was defined as p < 0.05, and p values were represented as follows: *p < 0.05, **p < 0.01, and ***p < 0.001.
To determine whether AQP5 deficiency causes ultrastructural changes, we performed transmission electron microscopy on lens capsule samples from Aqp5+/+ and Aqp5−/− mice. Compared to Aqp5+/+ controls, mitochondria in the lens epithelial cells of Aqp5−/− mice were markedly shrunken and mostly round or short rod-shaped (Figure 1A). Primary LECs from Aqp5+/+ and qp5−/− mice were analyzed for lipid peroxidation using C11-BODIPY581/591 staining. Aqp5−/− primary LECs exhibited significantly higher lipid peroxidation levels compared to Aqp5+/+ LECs (0.4441 ± 0.06912 versus 0.2812 ± 0.01845, p < 0.001; Figure 1B, C). Separately, intracellular Fe2+ levels were assessed using FerroOrange staining. Aqp5−/− primary LECs also showed a marked increase in intracellular Fe2+ accumulation relative to Aqp5+/+ controls (1.211 ± 0.1235 versus 1.000 ± 0.07540, p < 0.01; Figure 1D, E).
The Nrf2/SLC7A11/GPX4 axis was a key regulatory pathway that prevented ferroptosis by suppressing lipid peroxidation. Western blot analysis showed significantly lower protein levels of Nrf2, SLC7A11 (xCT light chain), SLC3A2 (xCT heavy chain), and GPX4 in Aqp5−/− mice compared to Aqp5+/+ controls (Nrf2: 0.5968 ± 0.1267 versus 1.000 ± 0.1949, p < 0.05; SLC7A11: 0.6311 ± 0.1710 versus 1.000 ± 0.05171, p < 0.05; SLC3A2: 0.6729 ± 0.1439 versus 1.000 ± 0.1117, p < 0.05; GPX4: 0.7643 ± 0.09894 versus 1.000 ± 0.03764, p < 0.05; Figure 1F, G).
To explore the potential link between AQPs and mitochondrial function, SRA01/04 cells were treated with AZ, a broad-spectrum aquaporin inhibitor. AQP inhibition by AZ was confirmed (Figure 2A). Key indicators of mitochondrial health were then evaluated. Compared with controls, AZ-treated cells showed significantly higher mtROS levels, reduced ΔΨm, and increased mPTP opening (Figure 2B–D).
AZ is an inhibitor of aquaporins. Since mouse lens epithelial cells express AQP0, AQP1, and AQP5, this study aimed to clarify AQP5’s role in mitochondrial function. We established an AQP5 knockdown model in SRA01/04 cells using lentivirus-mediated shRNA targeting AQP5. Efficient lentiviral transduction and reduced AQP5 protein expression were confirmed before further analysis (Figure 2E). The shAQP5 group showed significantly increased mtROS levels (2.588 ± 0.2634), decreased ΔΨm (0.8882 ± 0.2324), and increased mPTP opening (0.5083 ± 0.1105) compared to the control group (mtROS: 1.000 ± 0.2692, p < 0.001; ΔΨm: 0.2326 ± 0.1867, p < 0.001; mPTP: 1.000 ± 0.1072, p < 0.001; Figure 2F–H).
To explore the role of AQP5 in regulating ferroptosis, key phenotypic features of ferroptosis were evaluated in SRA01/04 cells after AQP5 knockdown. Compared to shNC cells (0.3377 ± 0.1637), shAQP5 cells showed significantly higher intracellular lipid peroxidation (1.059 ± 0.1959, p < 0.001), as measured by C11-BODIPY 581/591 staining (Figure 3A). Using FerroOrange and Mito-FerroGreen, we found that both total cellular and mitochondrial Fe2+ levels were significantly elevated in shAQP5 cells compared to shNC cells (total Fe2+: 1.358 ± 0.1033 versus 1.000 ± 0.1264, p < 0.001; mitochondrial Fe2+: 2.029 ± 0.2513 versus 1.000 ± 0.1315, p < 0.001; Figure 3B).
Western blot and immunofluorescence staining showed that Nrf2 protein levels were significantly lower in shAQP5 cells than in shNC cells (Figure 3C, D). To clarify the potential link between reduced Nrf2 expression and ferroptosis, we assessed the levels of SLC7A11, SLC3A2, and GPX4, key molecules that regulate Fe2+ homeostasis and prevent lipid peroxidation. Western blot analyses showed that the protein levels of SLC7A11, SLC3A2, and GPX4 were significantly lower in shAQP5 cells (SLC7A11: 0.7189 ± 0.06893; SLC3A2: 0.4928 ± 0.05595; GPX4: 0.7347 ± 0.08642) than in shNC cells (SLC7A11: 1.000 ± 0.06886, p < 0.01; SLC3A2: 1.000 ± 0.05006, p < 0.001; GPX4: 1.000 ± 0.1381, p < 0.05; Figure 3E). Immunofluorescence staining confirmed these results (Figure 3F).
Pharmacologic inhibition of AQPs by AZ produced similar effects, including increased lipid peroxides and Fe2+ accumulation (Appendix 1). The Nrf2–SLC7A11–GPX4 axis was also downregulated in AZ-treated cells (Appendix 1).
To confirm that Nrf2 activation can reverse ferroptosis caused by AQP5 deficiency, shAQP5-transduced SRA01/04 cells were treated with AT, a known pharmacologic activator of Nrf2 that promotes its nuclear translocation and transcriptional activity. Western blot showed that AT restored the expression of SLC7A11 (0.8587 ± 0.05216), SLC3A2 (0.9802 ± 0.1872), and GPX4 (1.151 ± 0.1268) compared to the control group (SLC7A11: 0.4222 ± 0.07734, p < 0.001; SLC3A2: 0.7123 ± 0.03868, p < 0.05; GPX4: 0.6169 ± 0.2011, p < 0.05; Figure 4A, B). Immunofluorescence results matched the western blot findings (Figure 4C, D).
Considering the critical role of mitochondrial integrity in regulating ferroptosis, we evaluated key indicators of mitochondrial function. AT treatment (mtROS: 1.132 ± 0.3707; JC-1: 0.3991 ± 0.1048; mPTP: 0.9360 ± 0.1059) significantly improved shAQP5-induced mitochondrial dysfunction (mtROS: 2.449 ± 0.1893, p < 0.001; JC-1: 0.5686 ± 0.04529, p < 0.01; mPTP: 0.6094 ± 0.05446, p < 0.001), as shown by reduced mtROS; restored ΔΨm polarization; and decreased mPTP activity (Figure 5A, B). AT intervention significantly reduced mitochondrial Fe2+ accumulation and lipid peroxide levels (Mito-FerroGreen: 1.196 ± 0.1979; Mito-PeDPP: 0.9493 ± 0.1224), compared to the shAQP5 group (Mito-FerroGreen: 2.197 ± 0.2110, p < 0.001; Mito-PeDPP: 1.865 ± 0.2419, p < 0.001; Figure 5C–F).
Activating Nrf2 can also effectively counteract AQP5 inhibition-induced ferroptosis, restore antioxidant protein expression, and improve mitochondrial function (Appendix 2).
The study examined Gal’s effect on inhibiting ferroptosis in SRA01/04 cells. Western blot and immunofluorescence analysis showed that Gal (SLC7A11: 1.017 ± 0.08325; SLC3A2: 1.087 ± 0.2089; GPX4: 1.128 ± 0.1299) significantly increased the expression of SLC7A11, SLC3A2, and GPX4 compared to the shAQP5 group (SLC7A11: 0.6344 ± 0.1292, p < 0.01; SLC3A2: 0.5983 ± 0.09406, p < 0.01; GPX4: 0.5499 ± 0.1622, p < 0.01; Figure 6A–D).
mtROS levels were significantly lower in shAQP5 + Gal cells than in the shAQP5 group (1.375 ± 0.2704 versus 2.179 ± 0.2466, p < 0.001). Following the Gal treatment of SRA01/04 cells with AQP5 knockdown, the ΔΨm showed recovery toward normal polarization (JC-1 ratio: 0.2774 ± 0.08289 versus 0.6231 ± 0.1103, p < 0.001), and mPTP opening was reduced (1.306 ± 0.1124 versus 0.5636 ± 0.05429, p < 0.001; Figure 6E, F).
Gal treatment significantly reduced mitochondrial Fe2+ and lipid peroxide accumulation in shAQP5 cells, as shown by decreased fluorescence intensity of Mito-FerroGreen (1.068 ± 0.1187 versus 2.652 ± 0.4241, p < 0.001) and Mito-PeDPP (0.7397 ± 0.1329 versus 1.768 ± 0.4622, p < 0.001; Figure 6G, H).
Although the aforementioned findings suggested Gal’s potential in inhibiting ferroptosis, its molecular mechanism in lens diseases remains unclear. Lenses from Aqp5−/− mice showed significant opacification. Administering either Fer-1 or Gal intraperitoneally improved lens opacity in Aqp5−/− mice compared to untreated controls (Figure 7A). Gal treatment significantly restored the protein expression levels of Nrf2, SLC7A11, SLC3A2, and GPX4 in Aqp5−/− mice (Nrf2: 1.638 ± 0.2228, p < 0.01; SLC7A11: 2.766 ± 0.2200, p < 0.001; SLC3A2: 2.347 ± 0.4862, p < 0.01; GPX4: 2.334 ± 0.1596, p < 0.01), indicating an effect comparable to that of Fer-1 treatment (Figure 7B, C).
To confirm that Gal’s antiferroptotic effect in vivo depends on Nrf2 activation, Aqp5−/− mice treated with Gal were also given Bru, a specific Nrf2 inhibitor. Cotreatment with Bru significantly reduced Gal’s protective effects. Slit-lamp analysis showed increased lens opacity in the Aqp5−/− + Gal + Bru group compared to the Aqp5−/− + Gal group (Figure 7D). Western blot results also showed lower levels of SLC7A11, SLC3A2, and GPX4 proteins in the Aqp5−/− + Gal + Bru group (SLC7A11: 0.7077 ± 0.1199; SLC3A2: 0.5102 ± 0.1091; GPX4: 0.3372 ± 0.09328) than in the Aqp5−/− + Gal group (SLC7A11: 1.000 ± 0.06209, p < 0.05; SLC3A2: 1.000 ± 0.2157, p < 0.05; GPX4: 1.000 ± 0.1681, p < 0.01; Figure 7E, F).
Age-related dysregulation of iron homeostasis is linked to various ocular diseases, including cataracts, glaucoma, keratopathy, retinitis pigmentosa, diabetic retinopathy, and retinoblastoma. This suggests ferroptosis may be critical in their pathogenesis [40]. Consistent with this notion, recent investigations have highlighted the pathogenic role of ferroptosis not only in cataracts but also in other ocular disorders such as diabetic retinopathy, in which inhibiting ferroptosis via activation of the Nrf2 pathway protects retinal endothelial cells from high glucose–induced injury [41,42]. Oxidative stress contributes to cataract development [43]. β-Amyloid monomers boost antioxidant capacity and reduce oxidative stress in LECs [44]. Nrf2 protects human LECs from hydrogen peroxide–induced stress [45]. At the cellular level, oxidative stress can trigger ferroptosis, a form of regulated cell death, to which aged LECs are particularly vulnerable [14,46]. The two key events initiating ferroptosis are intracellular iron accumulation and lipid peroxidation [20]. In our study, LECs from Aqp5−/− mice showed increased lipid peroxides and Fe2+ levels. To investigate whether human lens epithelial cells would exhibit similar changes upon AQP5 downregulation, SRA01/04 cells were treated with shAQP5. The results revealed enhanced lipid peroxidation and significant Fe2+ accumulation in both the cytoplasm and mitochondria of shAQP5-treated cells.
Mitochondria are the main source of reactive ROS, which sensitize cells to ferroptosis [47]. Ferroptosis causes significant changes in mitochondrial morphology, such as reduced volume, increased bilayer density, and loss of cristae [48]. The AMPK/FoxO3a axis modulates energy stress to regulate mitochondrial function and ferroptosis [49]. Our study showed that shAQP5 treatment increased mtROS production, decreased MMP, and enhanced mPTP opening in SRA01/04 cells, indicating mitochondrial dysfunction.
Ferroptosis is a key pathologic mechanism in cataract progression [50]. Relevant signaling pathways include System Xc-/GPX4, P62-Keap1-Nrf2, P53/SLC7A11, HSPB1-TRF1, and FSP1-COQ10-NAD(P)H [48]. Previous studies show ferroptosis in LECs of patients with ARC and aged mice [22]. Our findings indicated elevated lipid peroxidation and Fe2+ accumulation in Aqp5–/– mouse primary LECs. ShAQP5 treatment increased Fe2+ levels and lipid peroxides while inhibiting the Nrf2/SLC7A11/GPX4 pathway in SRA01/04 cells. These results suggested AQP5 deficiency sensitizes SRA01/04 cells to ferroptosis by suppressing this pathway.
The modulation of ferroptosis and oxidative stress affects cataract formation. ENST00000586817, an N6-methyladenosine–modified long noncoding RNA, may regulate GPX4 expression via cis-regulation, contributing to ferroptosis in ARC [51]. Melatonin inhibits ferroptosis by activating the SIRT6/p-Nrf2/GPX4 and SIRT6/COA4/FTH1 pathways, protecting cells from ferroptotic stress and delaying cataract progression in UVB-exposed rat models [52]. Glycine modulates cellular iron homeostasis by controlling lysosome-dependent ferritin degradation and PCBP2-mediated ferrous ion transport, slowing cataract development [50]. Additionally, GSK-3β–dependent Nrf2 antioxidant response regulates ferroptosis in LECs linked to ARC [22]. The ferroptosis inhibitor Fer-1 prevents cell death by reducing lipid peroxidation. It also protects the retina from light-induced degeneration [53]. AT exhibits antioxidant and anticancer effects by alleviating lipopolysaccharide (LPS)-induced oxidative stress and ferroptosis via the Nrf2/HO-1 and NF-κB pathways [54]. Collectively, our data demonstrated that AT and Fer-1 rescued AQP5 deficiency-induced mitochondrial dysfunction, consequently suppressing ferroptotic cascade execution.
Studies have shown that Gal alleviates ferroptosis induced by myocardial ischemia-reperfusion by targeting the Nrf2/Gpx4 signaling pathway [35]. The Nrf2-activating capacity of Gal is well documented; for example, it has been shown to mitigate neurotoxicity in Parkinson’s disease models by upregulating the Nrf2/Keap1 pathway [36]. It is worth noting that Gal can reverse the expression inhibition of key regulatory factors of ferroptosis (GPX4, Nrf2, ferroportin, and SLC7A11) induced by doxorubicin. In this study, based on our AQP5 deletion model (simulated by knocking down shRNA in SRA01/04 cells), we observed that Gal treatment increased the expression of Nrf2, SLC7A11, SLC3A2, and GPX4. Meanwhile, mitochondrial dysfunction is weakened, mtROS decrease, MMP recovers, and mitochondrial lipid peroxidation/Fe2+ accumulation reduces. It is worth noting that after Bru treatment, Gal had no effect on the Nrf2/SLC7A11/GPX4 signaling pathway.
A critical question raised by our findings is how AQP5 deficiency mechanistically leads to suppression of the Nrf2/SLC7A11/GPX4 axis. Classical AQP5 functions as a water channel, but recent evidence indicates that AQP5 can also transport H2O2 as a peroxiporin [55]. In this context, AQP5 deficiency may impair H2O2 efflux, leading to intracellular accumulation of ROS, which in turn suppresses Nrf2 activity and downstream antioxidant defenses. Alternatively, our data reveal that AQP5 deficiency causes mitochondrial dysfunction, including increased mtROS, reduced ΔΨm, and enhanced mPTP opening. Mitochondrial dysfunction can promote Fe2+ release and lipid peroxidation, creating a permissive environment for ferroptosis [56]. Thus, AQP5 may influence ferroptosis susceptibility through both its peroxiporin activity and its role in maintaining mitochondrial homeostasis. Although direct evidence of a physical association between AQP5 and mitochondria is currently lacking, our functional data indicate that AQP5 is required to maintain mitochondrial homeostasis in lens epithelial cells. Future studies should explore whether AQP5 localizes to mitochondria or physically interacts with mitochondrial regulatory proteins, which would provide mechanistic insight into how AQP5 deficiency leads to mitochondrial dysfunction and ferroptosis susceptibility.
In summary, AQP5 deficiency triggered mitochondrial ferroptosis in SRA01/04 cells by disrupting the Nrf2/SLC7A11/GPX4 axis, thereby driving cataractogenesis. Our data demonstrated that Gal mitigated AQP5 deficiency-induced ferroptosis in SRA01/04 cells and attenuated cataract phenotypes by targeting this pathway (Figure 8). These findings provide a new therapeutic perspective for delaying the occurrence and development of senile cataract by targeting ferroptosis through activating the Nrf2/SLC7A11/GPX4 pathway.
SPR and CH: Methodology, Supervision, Writing – original draft, Writing – review and editing. WXW: Methodology, Supervision, Writing – original draft, Writing – review and editing. ZKE: Methodology, Supervision, Validation. HWS and GY: Methodology, Supervision, Validation. DGH and WDQ: Conceptualization, Funding acquisition, Supervision, Writing – review and editing. CP and ZMH: Conceptualization, Funding acquisition, Supervision, Writing – review and editing. Declaration of conflicting interests The author(s) declared no potential conflicts of interest with respect to the, research, authorship, and publication of this article.Funding sources Shandong Provincial Natural Science Foundation grant (ZR2024MH199), the Shandong Provincial Youth Entrepreneurship Program for Colleges and Universities (2022KJ148), Hunan Provincial Natural Science Foundation grant (2024JJ9021, 2024JJ9025), and Qingdao demonstration programs for science and technology to benefit the people (24–2-8-smjk-9-nsh) .Dr. Peng Chen ([email protected]) and Dr. Minghong Zhang ([email protected]) are co-corresponding authors for this paper.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator. CC BY-NC-ND includes the following elements: BY: credit must be given to the creator. NC: Only noncommercial uses of the work are permitted. ND: No derivatives or adaptations of the work are permitted.